EA201391200A1 - Способы и композиции для вакцинации от staphylococcus aureus - Google Patents

Способы и композиции для вакцинации от staphylococcus aureus

Info

Publication number
EA201391200A1
EA201391200A1 EA201391200A EA201391200A EA201391200A1 EA 201391200 A1 EA201391200 A1 EA 201391200A1 EA 201391200 A EA201391200 A EA 201391200A EA 201391200 A EA201391200 A EA 201391200A EA 201391200 A1 EA201391200 A1 EA 201391200A1
Authority
EA
Eurasian Patent Office
Prior art keywords
staphylococcus aureus
mammal
vaccination
compositions
methods
Prior art date
Application number
EA201391200A
Other languages
English (en)
Other versions
EA035513B1 (ru
Inventor
Майкл Р. Йиман
Джон Е. Джр. ЭДВАРДС
Скотт Дж. Филлер
Ашраф С. Ибрагим
Юэ Фу
Джон П. Джр. Хеннеси
Original Assignee
ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика", Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер filed Critical ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика"
Publication of EA201391200A1 publication Critical patent/EA201391200A1/ru
Publication of EA035513B1 publication Critical patent/EA035513B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Изобретение предлагает способ вакцинации млекопитающего от Staphylococcus aureus,который включает этапы а) идентификации млекопитающего с риском развития инфекции Staphylococcus aureus на коже или мягкой ткани и b) введения упомянутому млекопитающему иммуногенного количества вакцины, которая включает полипептид, включающий выделенный белок 3 (Als3p) агглютинино-подобной последовательности (Als), или его иммуногенный фрагмент в фармацевтически приемлемой среде.
EA201391200A 2011-07-22 2012-07-20 ВАКЦИНА, СОДЕРЖАЩАЯ БЕЛОК Als3, ДЛЯ ЛЕЧЕНИЯ У МЛЕКОПИТАЮЩЕГО АБСЦЕССА КОЖИ, ОБУСЛОВЛЕННОГО STAPHYLOCOCCUS AUREUS EA035513B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22
PCT/US2012/000328 WO2013015831A1 (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Publications (2)

Publication Number Publication Date
EA201391200A1 true EA201391200A1 (ru) 2014-05-30
EA035513B1 EA035513B1 (ru) 2020-06-29

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391200A EA035513B1 (ru) 2011-07-22 2012-07-20 ВАКЦИНА, СОДЕРЖАЩАЯ БЕЛОК Als3, ДЛЯ ЛЕЧЕНИЯ У МЛЕКОПИТАЮЩЕГО АБСЦЕССА КОЖИ, ОБУСЛОВЛЕННОГО STAPHYLOCOCCUS AUREUS

Country Status (12)

Country Link
US (1) US10653757B2 (ru)
EP (1) EP2734229B1 (ru)
JP (1) JP2014521605A (ru)
CN (1) CN103998056B (ru)
AU (1) AU2012287513A1 (ru)
BR (1) BR112014001409A2 (ru)
CA (1) CA2842626A1 (ru)
EA (1) EA035513B1 (ru)
ES (1) ES2716800T3 (ru)
GE (1) GEP201706766B (ru)
UA (1) UA114286C2 (ru)
WO (1) WO2013015831A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2013015831A1 (en) 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
CN105263513A (zh) * 2013-03-14 2016-01-20 王荣福 调控调节性t细胞功能的方法和组合物
US11198724B2 (en) 2013-03-14 2021-12-14 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
BR112015022963A8 (pt) * 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
JP7439371B2 (ja) * 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2964721D1 (en) 1978-08-24 1983-03-17 Nat Res Dev Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
HU223707B1 (hu) 1995-06-07 2004-12-28 Pfizer Inc. Eimeria sporozoiták vagy merozoiták alkalmazása coccidiózis elleni in ovo vakcinázásra szolgáló vakcina előállítására
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
CA2847885C (en) 2001-11-30 2022-03-22 Amgen Fremont Inc. Transgenic animals bearing human ig.lambda. light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
MXPA06005639A (es) 2003-11-21 2006-08-17 Pfizer Prod Inc Adyuvante antimicrobiano.
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
RU2593945C2 (ru) 2006-04-17 2016-08-10 Интервет Интернэшнл Б.В., ПО СУЩЕСТВУ НЕТОКСИЧНЫЙ МУТЕИН АЛЬФА-ТОКСИНА Clostridium perfringens И КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ
US20080311135A1 (en) 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
RU2525587C2 (ru) 2008-05-29 2014-08-20 Интервет Интернэшнл Б.В. Вакцинная композиция для иммунизации животного против кокцидиоза и способ ее использования
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
CN107096020A (zh) 2009-06-22 2017-08-29 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
RU2015122387A (ru) 2009-07-03 2015-10-27 Лос-Анжелес Биомедикал Ресёрч Институт Эт Харбор-Укла Медикал Центер Hyr1 в качестве мишени для активной и пассивной иммунизации против candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
WO2013015831A1 (en) 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
UA114286C2 (uk) 2017-05-25
EP2734229A1 (en) 2014-05-28
US10653757B2 (en) 2020-05-19
AU2012287513A8 (en) 2014-06-19
WO2013015831A1 (en) 2013-01-31
JP2014521605A (ja) 2014-08-28
CA2842626A1 (en) 2013-01-31
CN103998056B (zh) 2017-09-12
US20150273031A1 (en) 2015-10-01
AU2012287513A1 (en) 2014-03-13
EA035513B1 (ru) 2020-06-29
BR112014001409A2 (pt) 2017-07-11
EP2734229B1 (en) 2019-01-02
CN103998056A (zh) 2014-08-20
GEP201706766B (en) 2017-10-25
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17

Similar Documents

Publication Publication Date Title
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
BR112014020019A2 (pt) vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
ATE461710T1 (de) Nipah-virus-impfstoffe
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
EA201391515A1 (ru) Инактивированная вакцина вируса денге
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
UA114719C2 (uk) Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
EA201690115A1 (ru) Комбинированные иммуногенные композиции
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA201500837A1 (ru) Парвовирус свиней 5в, способы применения и вакцина
BR112021020777A2 (pt) Vacina de subunidade do csfv
EA201690057A1 (ru) Остеопонтин молока млекопитающих для повышения иммунологической реактивности
WO2012078051A3 (en) IPN Vaccine
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU